Single-site Baseline and Short-term Outcomes of Clinical Characteristics and Life Quality Evaluation of Chinese Wet Age-related Macular Degeneration Patients in Routine Clinical Practice

Li-Li Wang, Wen-Jia Liu, Hai-Yun Liu, Xun Xu
Department of Ophthalmology, Shanghai First People’s Hospital, Shanghai 200080, China

Abstract

Background: Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among the older population. In China, treatment of age-related ocular diseases is becoming a priority in eye care services. This study was to investigate the clinical characteristics and quality of life of Chinese patients with wet AMD and current treatment types, to evaluate short-term gains in different treatments, and to investigate associations between visual function and vision-related quality of life (VRQoL).

Methods: A prospective, observational, noninterventional study was conducted. Basic data were collected from patients with clinical diagnoses of wet AMD before clinical assessments at baseline. VRQoL was measured with the Chinese version of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25). Correlations of the NEI VFQ-25 subscale scores with best-corrected visual acuity (BCVA) and between-group differences were analyzed.

Results: A total of 80 wet AMD patients were enrolled, with the mean age of 68.40 years. About one-quarter of wet AMD patients received intravitreal (IVT) ranibizumab treatment, and 67% of them were treated on a pro re nata basis. The visual acuity of patients treated with IVT ranibizumab at month 3 after treatment was significantly increased, whereas patients treated with traditional Chinese medicine achieved no significant improvement. Cronbach’s α for the NEI VFQ-25 subscales ranged from 0.697 to 0.843. Eight subscale and overall composite scores were moderately correlated with the BCVA of the better-seeing eye. Significant differences in the overall NEI VFQ-25 scores and other subscales were observed between patients with BCVA in the better-seeing eye of less than 50 letters and the others.

Conclusions: Patients treated with IVT ranibizumab experienced better vision improvement at short-term follow-up. The Chinese version of the NEI VFQ-25 is a valid and reliable tool for assessing the VRQoL of Chinese wet AMD patients.

Key words: Chinese Version of National Eye Institute Visual Function Questionnaire-25; Ranibizumab; Vision-related Quality of Life; Wet Age-related Macular Degeneration

INTRODUCTION

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss and blindness among the older population in most developed countries and some developing countries. In China, with the rapid growth of the aging population, age-related ocular diseases are becoming a priority in eye care services. AMD occurs in dry (also known as atrophic) and wet (also known as neovascular or exudative) forms, which usually results in blurred or distorted vision or even vision loss in the center of the visual field because of damage to the retina. [1-4] Wet AMD has a relatively low incidence, but if left untreated, severe visual impairment will occur. According to a previous report, the proportion of untreated wet AMD patients who developed severe vision loss increased from 21.3% at 6 months to 41.9% by 3 years. [5] Also, some studies showed a correlation between decreased visual function and vision-related quality of life (VRQoL) in AMD patients. In these studies, AMD-related visual impairment included psychological distress and reduction in participation of social events. [6-10]

The recent development of anti-vascular endothelial growth factor (VEGF) substances for use in ophthalmologic clinical treatments has markedly improved the prognosis of patients with wet AMD. Intravitreal (IVT) anti-VEGF treatments provide vision maintenance in more than 90% of patients and substantial improvement in 25–40% of patients. [11]
Ranibizumab was officially approved for the Chinese market as the first IVT anti-VEGF therapy drug in 2012, and it offered a new treatment choice for Chinese ophthalmologists and AMD patients. We therefore conducted this study in Shanghai, to evaluate the ocular characteristics of wet AMD patients and current treatment strategies in routine clinical practice in China. An additional purpose of this study was to evaluate disease development and the impact of VRQoL in wet AMD patients.

**Methods**

**Participants**

In this prospective, observational, noninterventional study design, the treatment choice was based on the decision of the physician only, regardless of study participation and treatment use. To be eligible for participation, patients were clinically diagnosed as having wet AMD in at least one eye. All patients were asked to follow-up every 3-month, and written informed consent was obtained from all participants. Patients who had received anti-VEGF treatment either systemically or intravitreously within the previous 90 days or who were currently participating in any other interventional study were not eligible.

**Clinical assessments**

The patients’ details included gender, age, educational level, profession, and risk factors such as hypertension, diabetes mellitus, smoking, cardiovascular disease, and history of stroke. Following collection of patients’ basic data, a comprehensive ocular assessment was performed including the best-corrected visual acuity (BCVA), dilated fundus examination, and fluorescein angiography detection, as well as optical coherence tomography (OCT) assessment of the macula. Due to the noninterventional approach of the study, the patients were assessed, diagnosed, and treated by retina specialists, and BCVA was measured by trained evaluators.

Best-corrected visual acuity was measured with a 4-m Early Treatment Diabetic Retinopathy Study (ETDRS) backlit lighthouse chart. The central retinal thickness (CRT) was obtained using Heidelberg Spectralis OCT (Heidelberg, German). The angiographic subtype of a patient’s lesion was defined in relation to the visualization of choroidal new vessels (classic) in the fluorescein angiogram. The total area of a predominantly classic lesion included more than 50% classic choroidal neovascularization (CNV), the total area of a minimally classic lesion included less than 50% classic CNV, and the total area of an occult lesion included no classic CNV. The greatest linear dimension (GLD) of a lesion, CNV, or leakage was measured on the fluorescein angiogram. Each patient was asked to follow-up at months 3, 6, 9, and 12. At baseline and each follow-up visit, BCVA, CRT, and treatment type were recorded. At baseline and month 12, the Chinese version of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) was administered.

**Vision-related quality of life**

Vision-related quality of life was evaluated using the Chinese version of the NEI VFQ-25. The questionnaire was administered by trained interviewers in a face-to-face interview format and was scored according to the guidelines provided by the instrument developers. The NEI VFQ-25 is composed of 25 questions that address 12 subscales that can be grouped together in three broad categories of subscales. The first category is the general health subscale (1 question), followed by the second category comprised of five subscales, which indicates the quality of vision and includes the general vision (1 question), near vision (3 questions), distance vision (3 questions), peripheral vision (1 question), and color vision (1 question) subscales. The third category is comprised of six subscales that assess the VRQoL: Dependency (3 questions), role limitations (2 questions), mental health (4 questions), social functioning (2 questions), ocular pain (2 questions), and driving (2 questions). The scores in Table 1 range from 0 (worst-possible VRQoL) to 100 (best-possible VRQoL), and a higher score indicates better visual function.

**Statistical analysis**

Demographic variables and clinical findings were summarized by descriptive analyses. Differences between mean values of multiple groups were analyzed by one-way analysis of variance with least squares deconvolution tests. The significance of the differences between BCVA and CRT of baseline and at 3-month follow-up were assessed using paired t-tests. The significance of associations between NEI VFQ-25 subscale scores and visual function was assessed using the Spearman correlation coefficient. A \( P < 0.05 \) was considered as statistically significant. All computations were performed with SPSS 17.0 (SPSS Inc., USA) software.

**Results**

**Baseline demographic and clinical characteristics**

A total of 80 wet AMD patients were enrolled in this single-site study, and 77 patients had completed the first follow-up at month 3. The mean age of the 80 participants was 68.40 years (standard deviation [SD], 9.76 years), and the mean age at AMD onset was 67.55 years (SD, 10.04 years). All participants were Han Chinese. Table 2 shows the demographic and clinical characteristics at the baseline.

**Table 1: NEI VFQ-25 subscales**

| Category                | Subscale                  | Number of questions |
|-------------------------|---------------------------|---------------------|
| 1-General health (1)    | General health            | 1                   |
| 2-Quality of vision (9) | General vision            | 1                   |
|                         | Near vision               | 3                   |
|                         | Distance vision           | 3                   |
|                         | Peripheral vision         | 1                   |
|                         | Color vision              | 1                   |
| 3-VRQoL (15)            | Dependency                | 3                   |
|                         | Role limitations          | 2                   |
|                         | Mental health             | 4                   |
|                         | Social functioning        | 2                   |
|                         | Ocular pain               | 2                   |
|                         | Driving                   | 2                   |

VRQoL: Vision-related quality of life; NEI VFQ-25: National Eye Institute Visual Function Questionnaire-25.
visit. Only one patient failed to finish the angiography because of an allergy. The fluorescein angiogram results showed that most cases were minimally classic, followed by predominantly classic, and occult with no classic. The mean GLD, represented by the lesion size of wet AMD in the studied eye was 3276.58 μm (SD, 2890.46 μm). Twenty-one participants received 0.5 mg ranibizumab IVT, among which seven patients received monthly therapy, whereas the other 14 patients were treated on a pro re nata (PRN) basis after the first IVT administration. Forty-one patients received traditional Chinese medicine (TCM) therapy at baseline, and two more changed to TCM at month 3. Photodynamic therapy (PDT) was suggested for only two patients, whereas the remaining 16 patients were asked to follow-up without any interventional treatments.

### Risk factors
More than 40% of the participants had hypertension; only four patients were diagnosed with diabetes and received treatments. Approximately, one-third of the enrolled participants were cigarette smokers, and Table 3 shows the smoking index (years of smoking × number of cigarettes per day).

### Best-corrected visual acuity
The mean BCVA of all patients at baseline was 33.45 letters (SD, 24.24 letters), and no differences were found among the four subgroups that received different treatment types. The mean BCVA at month 3 follow-up was 34.17 letters (SD, 23.75 letters), and patients who received ranibizumab IVT and PDT achieved significant BCVA improvement among the four subgroups [Table 4]. The mean BCVA increased from 45.00 (SD, 22.88) to 52.23 (SD, 22.17) letters in patients treated PRN based on OCT, whereas the monthly therapy group improved by about 11 letters (27.86 ± 18.45 to 38.43 ± 17.23). No significant difference was obtained between the two subgroups at baseline or month 3 (P > 0.05 each). No difference was observed between the BCVA of the TCM-treated and observation groups.

### Central retinal thickness
Optical coherence tomography measurements were available for each patient at baseline and the month 3 visit. The mean CRT at baseline for all patients was 492.44 μm (SD, 2890.46 μm) and decreased to 476.31 μm (SD, 282.60 μm) at month 3. The improvement in BCVA in IVT ranibizumab-treated patients was associated with CRT, which showed a significant reduction from baseline to the 3-month follow-up [Table 4].

### National Eye Institute Visual Function Questionnaire-25 scores and correlations with best-corrected visual acuity
As shown in Table 5, the subscale completion rate was 100%, except for the driving score (n = 5), because there are few elderly drivers in China. With the exception of vision-specific dependency (Cronbach’s α = 0.697), the subscales demonstrated a moderately strong internal consistency and reliability, with Cronbach’s α ranging from 0.711 to 0.834. As the response rate of the driving subscale was rather low in the present population, the Cronbach’s α was increased to a range of 0.869 to 0.912 when the driving subscale was omitted. The general vision, near vision, distance vision, peripheral vision, vision-related dependency, role limitations, mental health, social functioning, and overall composite scores were moderately correlated with the BCVA of the better-seeing eye. Better visual function scores were associated with higher scores on the overall NEI VFQ-25. This relation was exhibited for subgroups on the basis of both the better-seeing and worse-seeing eyes, but the association was stronger when the better-seeing eye visual function results were used [Table 6].

### National Eye Institute Visual Function Questionnaire-25 scores by best-corrected visual acuity letters
Except for the subscales of general health, color vision, and ocular pain, significant differences in the overall NEI VFQ-25 scores and other subscales were observed among the three subgroups: Better-seeing eye with a BCV A less than 11 letters (27.86 ± 18.45 to 38.43 ± 17.23). No significant difference was obtained between the two subgroups at baseline or month 3 (P > 0.05 each). No difference was observed between the BCVA of the TCM-treated and observation groups.

### Table 2: Patient’s baseline demographic and clinical characteristics

| Characteristics                  | n (%)      |
|----------------------------------|-----------|
| Gender                           |           |
| Female                           | 38 (47.5) |
| Male                             | 42 (52.5) |
| Educational level                |           |
| Primary school or less           | 11 (13.8) |
| Secondary school                 | 46 (57.5) |
| Tertiary school                  | 23 (28.8) |
| Distribution                     |           |
| Urban                            | 73 (91.3) |
| Rural                            | 7 (8.8)   |
| Profession                       |           |
| Medical worker                   | 7 (8.8)   |
| Farmer                           | 4 (5.0)   |
| Office-based worker              | 18 (22.5) |
| Worker                           | 17 (21.2) |
| Other                            | 34 (42.5) |
| Better or worse-seeing eye treated|          |
| Better-seeing eye                | 16 (20)   |
| Worse-seeing eye                 | 64 (80)   |
| Angiography lesion criteria      |           |
| Predominantly classic            | 29 (36.7) |
| Minimally classic                | 30 (38.0) |
| Occult with no classic           | 20 (25.3) |
| Treatment type (baseline/month 3) |          |
| Ranibizumab IVT                  | 21/6 (26.3/7.8) |
| Monthly injection                | 7 (7.5)   |
| PRN                              | 14 (18.8) |
| TCM                              | 41/43 (51.3/55.8) |
| PDT                              | 2/0 (2.5/0) |
| Observation                      | 16/28 (20.0/36.4) |

TCM: Traditional Chinese medicine; PDT: Photodynamic therapy; IVT: Intravitreal; PRN: Pro re nata.
driving subscale was omitted because the completion rate was rather low for comparison [Figure 1 and Tables 7,8].

**DISCUSSION**

According to a report from the Beijing Eye Study, 2.0% and 7.7% of low vision and blindness cases, respectively are caused by AMD in China.[12] Zou *et al.* reported that the prevalence of AMD in Shanghai residents over 50 years old is 15.5%, and that of wet AMD is 1.79%.[13] In this observational study focused on wet AMD, most of the participants were from Shanghai and had a relatively higher education level in the elderly population. The classifying type of CNV was based on fluorescein angiogram in our study, and we found that 38% of these patients were minimally classic, followed by predominantly classic, and occult, which is similar to the results of a previously reported VISION study[14] but differs from the results of the WAVE study in Germany.[15] It was reported that increased risks for wet AMD were associated with moderate to severe hypertension, cigarette smoking, higher levels of serum cholesterol, and cardiovascular disease.[16,17] In our study, more than 40% of the enrolled participants had definite hypertension and history of anti-hypertensive medication administration, and 28.8% were currently smoking cigarettes. Our results indicate that hypertension and smoking are likely the two greatest risk factors for wet AMD in the elderly Chinese population.

In China, anti-VEGF therapy, PDT, and TCM are currently the most common interventional treatments for wet AMD in routine clinic practice, and ranibizumab is now the only labeled IVT medicine for wet AMD. As shown in two major clinical trials, the comparison of Age-related Macular Degeneration Treatments Trials and the alternative treatments to inhibit VEGF in age-related choroidal neovascularization study, which compared continuous versus either PRN or discontinuous anti-VEGF IVT therapy, individualized treatments based predominantly on OCT decreased the mean number of injections, while the outcomes were similar.[18,19] In our study, 21 patients received one IVT ranibizumab treatment at baseline, 14 of whom were then treated as needed. Patients treated by PDT and TCM did not achieve a significant increase in ocular functions, which were represented by BCVA scores. However, we cannot ignore the fact that the cost of IVT ranibizumab must be borne by patients and caregivers in China. This financial burden may have limited some patients' choices or even doctors’ choices, especially when patients need multiple injections.

With progressive damage to the macula, AMD patients will experience a multitude of visual problems that significantly affect their mental health and quality of life. Given the importance of adding VRQoL assessments into medical practice and the increasing prevalence of AMD in today's aging population, it is critical to understand the impact of AMD on VRQoL and to accomplish the measurement of VRQoL in routine ophthalmologic practice.[20] The NEI VFQ-25 was found to be the most commonly used psychometric tool to evaluate the VRQoL,[21] and it has been validated in patients with wet AMD in the United States. The Chinese version of the NEI VFQ-25 was also shown to be a valid and reliable instrument to measure VRQoL in Chinese patients with visual impairment.[22-24] The subscale scores of distance

![Figure 1: National Eye Institute Visual Function Questionnaire-25 overall and subscale scores by best-corrected visual acuity (BCVA) letters. The BCVA of the better-seeing eye was divided into three subgroups: Less than 50 letters (n = 13), 51–69 letters (n = 28), and more than 70 letters (n = 39).](image)

**Table 3: Risk factors for wet AMD**

| Risk factors         | n (%) | History of onset/smoking index (mean ± SD) |
|----------------------|-------|------------------------------------------|
| Hypertension         | 33 (41.2) | 13.00 ± 10.51                              |
| Diabetic             | 4 (5.0)   | 8.75 ± 5.32                               |
| Stroke               | 2 (2.5)    | 6.00 ± 5.66                               |
| Cardiovascular disease | 5 (6.2)   | 7.20 ± 4.32                               |
| Smoking              | 23 (28.8)  | 501.61 ± 434.24                           |

SD: Standard deviation; AMD: Age-related macular degeneration.

**Table 4: Analysis of BCVA and CRT changes between baseline and M3 follow-up**

| Variables                  | Ranibizumab | TCM | PDT | Observation |
|----------------------------|-------------|-----|-----|-------------|
| Baseline BCVA (letters, mean ± SD) | 39.29 ± 2.61 | 30.85 ± 24.10 | 24.50 ± 26.16 | 33.56 ± 27.27 |
| Baseline CRT (μm, mean ± SD)   | 475.00 ± 232.16 | 497.44 ± 276.39 | 668.00 ± 158.39 | 480.56 ± 362.89 |
| M3 BCVA (letters, mean ± SD)   | 47.40 ± 21.21 | 29.62 ± 23.51 | 26.00 ± 26.87 | 29.75 ± 22.88 |
| M3 CRT (μm, mean ± SD)        | 402.80 ± 210.59 | 494.33 ± 273.30 | 598.50 ± 82.73 | 487.12 ± 363.35 |

P (baseline to M3 BCVA) | 0.008 | 0.165 | 0.205 | 0.088 |
| P (baseline to M3 CRT)  | 0.007 | 0.632 | 0.418 | 0.691 |

M3: Month 3; BCVA: Best-corrected visual acuity; CRT: Central retinal thickness; SD: Standard deviation; TCM: Traditional Chinese medicine; PDT: Photodynamic therapy.
The BCVA of the better-seeing eye was divided into three subgroups: Less than 50 letters \((n = 13)\), 51–69 letters \((n = 28)\), and more than 70 letters \((n = 39)\) NEI VFQ-25: National Eye Institute Visual Function Questionnaire-25.

**Table 6: Correlations between NEI VFQ-25 subscale scores and BCVA**

| NEI VFQ-25 subscale | Spearman rank-order correlation coefficient \((r)\) | Better-seeing eye BCVA (letters) |  | Worse-seeing eye BCVA (letters) |  |
|---------------------|-----------------------------------------------|-------------------------------|---|-------------------------------|---|
| General health      | \(-0.11\)                                     | 0.923                         | 0.130 | 0.249                         | 0.130 |
| General vision      | 0.563                                         | 0.000                         | 0.218 | 0.052                         | 0.218 |
| Near vision         | 0.552                                         | 0.000                         | 0.292 | 0.009                         | 0.292 |
| Distance vision     | 0.523                                         | 0.000                         | 0.303 | 0.006                         | 0.303 |
| Peripheral vision   | 0.448                                         | 0.000                         | 0.358 | 0.001                         | 0.358 |
| Color vision        | 0.155                                         | 0.169                         | 0.082 | 0.469                         | 0.082 |
| Dependency          | 0.568                                         | 0.000                         | 0.240 | 0.032                         | 0.240 |
| Role limitations    | 0.452                                         | 0.001                         | 0.095 | 0.403                         | 0.095 |
| Mental health       | 0.496                                         | 0.000                         | 0.147 | 0.193                         | 0.147 |
| Social functioning  | 0.231                                         | 0.039                         | 0.272 | 0.015                         | 0.272 |
| Ocular pain         | 0.021                                         | 0.853                         | 0.016 | 0.888                         | 0.016 |
| Driving             | 0.211                                         | 0.734                         | 0.222 | 0.720                         | 0.222 |
| Overall composite score | 0.530                                  | 0.000                         | 0.280 | 0.012                         | 0.280 |

**Table 7: Comparisons of NEI VFQ-25 scores by BCVA subgroup**

| NEI VFQ-25 subscale | \(P\) value for comparison of subgroup A with B | \(P\) value for comparison of subgroup A with C | \(P\) value for comparison of subgroup B with C |
|---------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| General health      | 0.733                                         | 0.768                                         | 0.399                                         |
| General vision      | 0.025                                         | 0.000                                         | 0.007                                         |
| Near vision         | 0.002                                         | 0.000                                         | 0.004                                         |
| Distance vision     | 0.032                                         | 0.000                                         | 0.000                                         |
| Peripheral vision   | 0.013                                         | 0.000                                         | 0.014                                         |
| Color vision        | 0.282                                         | 0.103                                         | 0.509                                         |
| Dependency          | 0.003                                         | 0.000                                         | 0.001                                         |
| Role limitations    | 0.026                                         | 0.002                                         | 0.292                                         |
| Mental health       | 0.010                                         | 0.000                                         | 0.070                                         |
| Social functioning  | 0.011                                         | 0.004                                         | 0.727                                         |
| Ocular pain         | 0.157                                         | 0.388                                         | 0.420                                         |
| Overall composite score | 0.001                                   | 0.000                                         | 0.005                                         |

**Table 8: National Eye Institute Visual Function Questionnaire-25 overall and subscale scores by best-corrected visual acuity (BCVA) letters**

| NEI VFQ-25 subscale | \(\leq 50\) letters | 51–69 letters | \(\geq 70\) letters |
|---------------------|---------------------|---------------|---------------------|
| General health      | 42.31               | 44.64         | 40.38               |
| General vision      | 40                  | 50            | 58.97               |
| Near vision         | 46.8                | 69.79         | 85.9                |
| Distance vision     | 46.8                | 64.14         | 86.22               |
| Peripheral vision   | 76.92               | 88.39         | 96.79               |
| Color vision        | 94.23               | 97.32         | 97.5                |
| Dependency          | 32.69               | 56.25         | 76.5                |
| Role limitations    | 30.77               | 49.11         | 55.45               |
| Mental health       | 42.31               | 58.7          | 67.15               |
| Social functioning  | 80.77               | 93.3          | 94.55               |
| Ocular pain         | 80.77               | 87.95         | 84.94               |
| Overall score       | 51.57               | 67.08         | 77.09               |

NA: Not applicable; SD: Standard deviation; NEI VFQ-25: National Eye Institute Visual Function Questionnaire-25.

Our study, the correlations of VFQ-25 subscale scores with better-seeing eye BCVA were more significant than those with worse-seeing eye BCVA, and patients with a better-seeing eye BCVA more than 60 letters achieved significantly elevated scores for the overall composite score. However, the costs of these clinical measurements were included. In addition, the response rate for the driving subscale was only 6.25% in our study. It has been demonstrated in some studies that the driving subscale has poor construct validity and reliability[26,27] and most older adults in China do not drive, especially when they
suffer from impaired vision. Therefore, the driving subscale was not very practicable among Chinese AMD patients, which indicates that further adjustment is needed in future studies.

In conclusion, the baseline and short-term follow-up results from this observational, noninterventional study suggest that about one-quarter of wet AMD patients in China receive anti-VEGF IVT treatment in routine clinical practice, and two-thirds of them were treated PRN guided by OCT measurements. IVT ranibizumab helps wet AMD patients obtain a greater increase in visual function than TCM. The Chinese version of the NEI VFQ-25 is a valid and reliable tool for assessing the visual function and life quality of Chinese patients with wet AMD. Wet AMD patients with damaged vision have lower VRQoL, which was related to the better-seeing eye BCVA, especially when the BCVA of the better-seeing eye was less than 50 ETDRS letters. However, this single-site study in Shanghai cannot represent the entire population in China, and studies of larger samples across multiple centers are needed. Longitudinal follow-up is now undergoing, and the results may aid assessments of the impact of different treatments on the VRQoL of wet AMD patients.

REFERENCES

1. Kawasaki R, Yasuda M, Song SJ, Chen SJ, Jonas JB, Wang JJ, et al. The prevalence of age-related macular degeneration in Asians: A systematic review and meta-analysis. Ophthalmology 2010;117:921-7.
2. Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA 2003;290:2057-60.
3. Friedman DS, O’Colmain BI, Muñoz B, Tomany SC, McCarty C, de Jong PT, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72.
4. Klein R, Klein BE, Knudtson MD, Wong TY, Cotch MF, Liu K, et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology 2006;113:373-80.
5. Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, et al. The natural history and progression of neovascular age-related macular degeneration: A systematic review of the literature and meta-analysis. Ophthalmology 2008;115:116-26.
6. Mackenzie PJ, Chang TS, Scott IU, Linder M, Hay D, Feuer WJ, et al. Assessment of vision-related function in patients with age-related macular degeneration. Ophthalmology 2002;109:720-9.
7. Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol 1998;116:514-20.
8. Scott IU, Feuer WJ, Jacko JA. Impact of visual function on computer task accuracy and reaction time in a cohort of patients with age-related macular degeneration. Am J Ophthalmol 2002;133:350-7.
9. Clemons TE, Chew EY, Bressler SB, McWee B, Age-Related Eye Disease Study Research Group. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No 10. Arch Ophthalmol 2003;121:211-7.
10. Orr P, Rentz AM, Margolis MK, Revicki DA, Dolan CM, Colman S, et al. Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related macular degeneration. Invest Ophthalmol Vis Sci 2011;52:3354-9.
11. Schmidt-Erfurth UM, Pruente C. Management of neovascular age-related macular degeneration. Prog Retin Eye Res 2007;26:437-51.
12. Xu L, Wang Y, Li Y, Wang Y, Cui T, Li J, et al. Causes of blindness and visual impairment in urban and rural areas in Beijing: The Beijing Eye Study. Ophthalmology 2006;113:1134.e11-11.
13. Zou HD, Zhang X, Xu X, Wang FH, Zhang SJ. Prevalence study of age-related macular degeneration in Caojiadu blocks, Shanghai (in Chinese). Chin J Ophthalmol 2005;41:15-9.
14. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
15. Finger RP, Wiedemann P, Bluhmagen F, Pohl K, Holz FG. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study – A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 2013;91:540-6.
16. Risk factors for neovascular age-related macular degeneration. The Eye Disease Case-Control Study Group. Arch Ophthalmol 1992;110:1701-8.
17. Hyman L, Schachat AP, He Q, Leske MC. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch Ophthalmol 2000;118:351-8.
18. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology 2012;119:1388-98.
19. IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411.
20. Yuzawa M, Fujita K, Tanaka E, Wang EC. Assessing quality of life in the treatment of patients with age-related macular degeneration: Clinical research findings and recommendations for clinical practice. Clin Ophthalmol 2013;7:1325-32.
21. Marella M, Pesudovs K, Keeffe JE, O’Connor PM, Rees G, Lamoureux EL. The psychometric validity of the NEI VFQ-25 for use in a low-vision population. Invest Ophthalmol Vis Sci 2010;51:2878-84.
22. Lin JC, Chie WC. Psychometric validation of the Taiwan Chinese version of the 25-item National Eye Institute Visual Functioning Questionnaire. J Eval Clin Pract 2010;16:619-26.
23. Chan CW, Wong D, Lam CL, McGhee S, Lai WW. Development of a Chinese version of the National Eye Institute Visual Function Questionnaire (CHI-VFQ-25) as a tool to study patients with eye diseases in Hong Kong. Br J Ophthalmol 2009;93:1431-6.
24. Wang CW, Chan CL, Jin HY. Psychometric properties of the Chinese version of the 25-item National Eye Institute Visual Function Questionnaire. Optom Vis Sci 2008;85:1091-9.
25. Brown GC. Vision and quality-of-life. Trans Am Ophthalmol Soc 1999;97:473-511.
26. Globe D, Varma R, Azen SP, Paz S, Yu E, Preston-Martin S, et al. Psychometric performance of the NEI VFQ-25 in visually normal Latinos: The Los Angeles Latino Eye Study. Invest Ophthalmol Vis Sci 2003;44:1470-8.
27. Nordmann JP, Viali M, Sullivan K, Arnould B, Berdeaux G. Psychometric Validation of the National Eye Institute Visual Function Questionnaire – 25 (NEI VFQ-25) French version: In a population of patients treated for ocular hypertension and glaucoma. Pharmacoeconomics 2004;22:197-206.

Received: 26-11-2014 Edited by: Li-Shao Guo

How to cite this article: Wang LL, Liu WJ, Liu HY, Xu X. Single-site Baseline and Short-term Outcomes of Clinical Characteristics and Life Quality Evaluation of Chinese Wet Age-related Macular Degeneration Patients in Routine Clinical Practice. Chin Med J 2015;128:1154-9.

Source of Support: This work was supported by a grant from Novartis China (No. CRFB002ACN02). Conflict of Interest: None declared.